Disease relevance of Tiotrifar

• Anetholtrithion stabilizes body weight fluctuation caused by excessive water drinking in a patient with schizophrenia: a case report [1].
• In addition, this study supports the beneficial effects of anethole trithione in treating drug-induced xerostomia [2].
• Xerostomia due to Sjögren's syndrome. Diagnostic criteria, treatment and outlines for a continuous dental care programme and an open trial with Sulfarlem [3].
• METHODS: A cholagogue, anethole trithione (AT) was administered to patients with symptomatic hyposalivation (xerostomia) caused by senile hypofunction (4 men and 17 women; senile group), medications (6 men and 17 women; drug group), and oral cancer therapy (two men and three women; cancer group) [4].

High impact information on Tiotrifar

• The objective of this study was to determine the in vitro capacity of the aminothiol WR-1065, the active metabolite of amifostine, and anetholedithiolethione (ADT or Sulfarlem) to protect bovine lens epithelial cells against x-ray irradiation [5].
• Inhibition of NF-kappa B activation in human T-cell lines by anetholdithiolthione [6].
• Effects of chronic anethole trithione and amitriptyline treatment on rat parotid gland signalling [2].
• To evaluate the relative bioavailability of anethole trithione (ATT) from self-microemulsifying drug delivery system (SMEDDS) and tablet, a sensitive, accurate and reliable liquid chromatography method was developed and validated to determine ATT in rabbit plasma [7].
• HPLC determination of anethole trithione and its application to pharmacokinetics in rabbits [7].

Biological context of Tiotrifar

• It is concluded that Sulfarlem in a daily dose of 75 mg have no marked effect on salivation in patients with primary SS and severe xerostomia [8].

Anatomical context of Tiotrifar

• Acute effects of a possible sialogogue, anethole trithione, in rat parotid glands [9].
• Enhancement of phosphatidylinositol turnover and cyclic nucleotide accumulation by chronic anethole trithione treatment in rat submaxillary glands [10].
• Effect on salivary secretion of a single dose and of chronic treatment with trithio-p-methoxyphenylpropene (anethole trithione; ANTT) was investigated in mice, rats and rabbits in relation to changes in function of the autonomic nervous system [11].

Associations of Tiotrifar with other chemical compounds

• Chronic anethole trithione treatment enhances the salivary secretion and increases the muscarinic acetylcholine receptors in the rat submaxillary gland [12].
• Chronic treatment with trithio-p-methoxyphenylpropene (anethole trithione; ANTT) increased the salivary secretion from the rat submaxillary gland induced by electrical stimulation of the parasympathetic nerve and by injection of pilocarpine [12].

Gene context of Tiotrifar

• In particular the dithiolthione SULFARLEM, used as anticholestatic drug for more than 40 years, is shown to be antioxidant; preliminary pharmacokinetic data in man are presented, and hepatoprotective and radioprotective effect in mice are demonstrated [13].

Analytical, diagnostic and therapeutic context of Tiotrifar

• We present our current programme for oral and dental care of xerostomia patients and the results of an open trial with Sulfarlem (trithioparamethoxyphenylpropene) which was found not to be the drug of choice in the treatment of dry mouth associated with SS [3].

References